The export performance of biopharma is up

Twenty-four companies experienced an export sales increase KRW 3.7T→KRW 4.9T (first half-year period) over the year

17 of 24 companies had increased sales…Samsung Biosciences 33%·Celltrion 50%·SK Biopharm 76%↑

The export performance of two out of three pharmaceutical and biotech companies is reported to have increased year-over-year (YoY).

 

The total export sales of 24 companies increased from KRW 3.6869 trillion to KRW 4.8975 trillion over the year, up 33%.

 

In particular, the export performance of Samsung Biologics, Celltrion, and SK Biopharmaceuticals has substantially improved.

 

Samsung Biologics' export sales increased by over KRW 500 billion over the year, recording over KRW 2 trillion in export sales in the first half of the year.

 

Export sales of Celltrion and SK Biopharmaceuticals increased by over 50% YoY.

 

Export sales↑in 17 out of 24 listed pharmaceutical companies…Celltrion·SK Biopharm over 50% up According to the Financial Supervisory Service (FSS) on September 9th, the total export sales of twenty-four major pharmaceutical and biotech companies were KRW 4.8975 trillion in the first half 2024, up 33% YoY from KRW 3.6869 trillion last year.

 

This is the result of summing twent-four KOSPI-and KOSDAQ-listed pharmaceutical and biotech companies that have generated over KRW 10 billion in export sales.

 

The subsidiaries have been excluded from the calculation.

 

Seventeen of the twenty-four companies investigated had increased export performance compared to the same period last year.

 

The export performance of Celltrion, SK Biopharmaceuticals, Dong-wha, and Yungjin Pharmaceutical increased by over 50% over the year.

 

Those of Samsung Biologics, Yuhan Corp, Jeil Pharm, Hugel, and PharmaResearch increased by over 20%.

 

The export performance of Medytox, Hanmi Pharm, Kolon Life Science, Chong Kun Dang, Dongkook Pharmaceutical, Daewoong Pharmaceutical, and HK inno.N increased by over 10%.

 

DONG-A ST remained the same as last year.

 

In contrast, the export performance of Ilyang Pharmaceutical, ST Pharm, Korea United Pharm, GC Biopharma, Huons, SK Biosciences, and Kyongbo Pharmaceutical decreased from the same period last year.

 

Samsung Biologics has increased export to Europe·U.S….will it surpass KRW 4 trillion by the end of the year? Samsung Biologics recorded over KRW 2 trillion in export sales in the first half of the year alone.

 

It indicated a 33% increase from KRW 1.5399 trillion in the first half of last year to KRW 2.0298 trillion in the first half of this year.

 

Samsung Biologics has made a breaking record in export sales every year.

 

The company recorded KRW 1.2217 trillion in 2021, KRW 2.8466 in 2022, and KRW 3.5800 in 2023.

 

This year, over KRW 4 trillion in export sales is expected till the end of the year.

 

The total export sales Samsung Biologics generated since 2015 amount to US$13.055 billion (about KRW 17.36 trillion).

 

The company has delivered US$6.901 billion worth of products and US$6.142 billion (KRW 8.13 trillion) remains a backlog of orders.

 

If the company succeeds in product development, the backlog will increase to US$12.607 billion (about 16.84 trillion).

 

Samsung Biologics export sales by countries (unit: KRW 100 million, source: FSS).

The exports to all countries increased compared to the same period last year.

 

European exports increased by 22%, from KRW 1.0637 trillion to KRW 1.3001 trillion.

 

The U.S.

 

exports increased by 50%, from KRW 384.9 billion to KRW 576.3 billion.

 

Export to other countries increased by 32%, from KRW 91.3 billion to KRW 153.4 billion.

 

Celltrion surpassed KRW 1 trillion in the first half of the year…SK Biopharm sales 72% UP following Xcopri sales increase Celltrion surpassed KRW 1 trillion in export sales in the first half of the year.

 

It increased by 50% from KRW 947.1 billion in the first half of last year to KRW 1.4252 trillion in the first half of this year.

 

Exports to European and North American markets substantially increased.

 

Celltrion's exports to Europe increased from KRW 487.5 billion to KRW 689.3 billion.

 

Based on Celltrion's analysis, its maximized direct sales have contributed to increased sales of all products.

 

Remsima IV and SC formulations recorded positive sales in the U.K.

 

and Netherlands.

 

Furthermore, Yuflyma contributed to the sales increase after successfully entering the European countries.

 

Exports to North America increased by 79%, from KRW 274.6 billion to KRW 490.3 billion.

 

Inflectra generated sales in the North American market, and the sales of follow-up products are increasing.

 

As the sales of Inflectra increased, Celltrion added the DP manufacturing plant.

 

Celltrion expects the exports to North America to increase even more.

 

The company expects simultaneous growth in Inflectra and Zymfentra sales in the U.S., similar to the increase in Remsima IV sales following the launch of the SC formulation in Europe.

 

Celltrion export sales by countries (unit: KRW 100 million, source: FSS).

SK Biopharmceuticals' export sales increased by 76% from KRW 137.8 billion to KRW 242 billion.

 

The analysis suggests an increase in Xcopri's sales in the United States contributed to this.

 

Xcopri generated KRW 105.2 billion in sales in the U.S.

 

market in Q2, the first time Xcopri sales have exeeded KRW 100 billion in the U.S.

 

market.

 

SK Biopharmaceuticals launched Xcopri in the U.S.

 

market in Q2 2020.

 

Sales surpassed KRW 30 billion in Q1 2022, KRW 50 billion in Q1 2023, and KRW 100 billion this year.

 

Earlier this year, SK Biopharmaceuticals set a sales goal for U.S.

 

sales between US$ 300 million (about KRW 410 billion) and US$320 million (about KRW 440 billion).

 

With this trend, the company expects to reach its goal soon.